Blood Test for Traumatic Brain Injury

11/20/2017 - 3:00pm
Jackson Streeter, M.D., Chief Executive Officer, Florida Institute for the Commercialization of Public Research, Chief Medical Officer, Banyan Biomarkers, Inc.
Communicore, C1-17

Currently, no blood test exists for use by physicians to detect the presence and severity of brain trauma. Traumatic brain injury is one of the most common neurological disorders and a leading cause of death and disability in the US. This test may also be used for detection of sports related concussion and Banyan has been conducting research at the University of Florida on sports concussion with funding from the NFL and GE.

Banyan Biomarkers, Inc. is creating the first blood test to diagnose traumatic brain injury (TBI). The company was founded by scientists from the University of Florida McKnight Brain Institute with the vision to commercialize in vitro diagnostic tests for the detection of brain injury and neurological diseases. Following a brain injury, a destructive cascade of biological events continues over hours and days that may worsen the patient’s condition. Banyan has recently completed a large international phase 3 study and an application to the FDA is under review. In this presentation, I will discuss how we have discovered two protein biomarkers that rapidly appear in the blood of patients soon after injury and have developed biomarker assays to quantify these proteins. The identification and quantification of these two biomarkers will be used by physicians to rapidly detect the presence of TBI and improve the medical management of head injured patients.


In March 2016, Jackson Streeter M.D. assumed the role of CEO of the Florida Institute for the Commercialization of Public Research (the Institute). The Institute is a diversified early stage fund for Florida based companies and has 72 portfolio companies to date. The fund has generated over $970M in economic impact and state funding has been matched 7:1 in private investment. Dr. Streeter previously served as the CEO of Banyan Biomarkers, Inc. from 2010 to 2016. As CEO of Banyan Biomarkers, the company received over $70M from the Dept. of Defense and NIH, and raised $11M in private investment for the development of a first ever blood test for traumatic brain injury. Prior to joining Banyan Biomarkers, Dr. Streeter served as the Founder, CEO and Chief Scientific Officer of PhotoThera, Inc. During his tenure at PhotoThera, Dr. Streeter raised over $120M of invested capital and was responsible for the design and management of five U.S. and international clinical trials. He was also the co-founder of American Veterinary Laser which was acquired in a private transaction. He is the inventor on over twenty patents and author on multiple scientific publications. He is the winner of the Zone ventures entrepreneur and Adaptive Business Leader awards. Dr. Streeter served as a member of the Governor’s Life Science Task Force for the State of Florida and FBI counter terrorism southeast working group. He currently serves on the Wallace H. Coulter Center for Translational Research Oversight Committee, Sid Martin Biotechnology Incubator board, and Cade Museum board. Dr. Streeter earned his B.S. degree in Biology from the University of Nevada Reno and his M.D. from the University of Nevada School of Medicine.

Prior to becoming a medical industry executive, Dr. Streeter served as an Officer in the U.S. Navy, completing a general surgery internship at Naval Regional Medical Center in Portsmouth, Virginia and then primary Flight School at Naval Air Station in Pensacola, Florida. During his military service, Dr. Streeter was the first Naval Flight Surgeon selected as a TOPGUN staff instructor, served on several overseas deployments and was awarded the Navy Achievement Medal (2) and the Navy Commendation Medal.